OBJECTIVE: Evaluate the reliability and validity of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) in Hispanics with mild-to-moderate chronic kidney disease (CKD). DESIGN: Cross-sectional SETTING: Chronic Renal Insufficiency Cohort Study PARTICIPANTS: 420 Hispanic (150 English- and 270 Spanish-speakers), and 409 non-Hispanic White individuals, matched by age (mean 57 years), sex (60% male), kidney function (mean estimated glomerular filtration rate 36ml/min/1.73m2), and diabetes (70%). METHODS: To measure construct validity, we selected instruments, comorbidities, and laboratory tests related to at least one KDQOL-36 subscale. Reliability was determined by calculating Cronbach's alpha. RESULTS: Reliability of each KDQOL-36 subscale [SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS), Symptoms/Problems, Burden of Kidney Disease and Effects of Kidney Disease] was very good (Cronbach's alpha >0.8). Construct validity was supported by expected negative correlation between MCS scores and the Beck Depression Inventory in all three subgroups (r=-0.56 to -0.61, P<.0001). There was inverse correlation between the Symptoms/ Problems subscale and the Patient Symptom Form (r= -0.70 to -0.77, P<.0001). We also found significant, positive correlation between the PCS score and a physical activity survey (r=+0.29 to +0.38, P< or =.003); and between the PCS and MCS scores and the Kansas City Questionnaire (r= +0.31 to +0.64, P<.0001). Reliability and validity were similar across all racial/ethnic groups analyzed separately. CONCLUSION: Our findings support the use of the KDQOL-36 as a measure of HRQOL in this cohort of US Hispanics with CKD.
OBJECTIVE: Evaluate the reliability and validity of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) in Hispanics with mild-to-moderate chronic kidney disease (CKD). DESIGN: Cross-sectional SETTING:Chronic Renal Insufficiency Cohort Study PARTICIPANTS: 420 Hispanic (150 English- and 270 Spanish-speakers), and 409 non-Hispanic White individuals, matched by age (mean 57 years), sex (60% male), kidney function (mean estimated glomerular filtration rate 36ml/min/1.73m2), and diabetes (70%). METHODS: To measure construct validity, we selected instruments, comorbidities, and laboratory tests related to at least one KDQOL-36 subscale. Reliability was determined by calculating Cronbach's alpha. RESULTS: Reliability of each KDQOL-36 subscale [SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS), Symptoms/Problems, Burden of Kidney Disease and Effects of Kidney Disease] was very good (Cronbach's alpha >0.8). Construct validity was supported by expected negative correlation between MCS scores and the Beck Depression Inventory in all three subgroups (r=-0.56 to -0.61, P<.0001). There was inverse correlation between the Symptoms/ Problems subscale and the Patient Symptom Form (r= -0.70 to -0.77, P<.0001). We also found significant, positive correlation between the PCS score and a physical activity survey (r=+0.29 to +0.38, P< or =.003); and between the PCS and MCS scores and the Kansas City Questionnaire (r= +0.31 to +0.64, P<.0001). Reliability and validity were similar across all racial/ethnic groups analyzed separately. CONCLUSION: Our findings support the use of the KDQOL-36 as a measure of HRQOL in this cohort of US Hispanics with CKD.
Authors: Donna L Mapes; Jennifer L Bragg-Gresham; Jürgen Bommer; Shunichi Fukuhara; Patricia McKevitt; Björn Wikström; Antonio Alberto Lopes Journal: Am J Kidney Dis Date: 2004-11 Impact factor: 8.860
Authors: Jeannette G Van Manen; Johanna C Korevaar; Friedo W Dekker; Elisabeth W Boeschoten; Patrick M M Bossuyt; Raymond T Krediet Journal: J Am Soc Nephrol Date: 2003-02 Impact factor: 10.121
Authors: Donna L Mapes; Antonio Alberto Lopes; Sudtida Satayathum; Keith P McCullough; David A Goodkin; Francesco Locatelli; Shunichi Fukuhara; Eric W Young; Kiyoshi Kurokawa; Akira Saito; Jürgen Bommer; Robert A Wolfe; Philip J Held; Friedrich K Port Journal: Kidney Int Date: 2003-07 Impact factor: 10.612
Authors: Harold I Feldman; Lawrence J Appel; Glenn M Chertow; Denise Cifelli; Borut Cizman; John Daugirdas; Jeffrey C Fink; Eunice D Franklin-Becker; Alan S Go; L Lee Hamm; Jiang He; Tom Hostetter; Chi-Yuan Hsu; Kenneth Jamerson; Marshall Joffe; John W Kusek; J Richard Landis; James P Lash; Edgar R Miller; Emile R Mohler; Paul Muntner; Akinlolu O Ojo; Mahboob Rahman; Raymond R Townsend; Jackson T Wright Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: Anna C Porter; James P Lash; Dawei Xie; Qiang Pan; Jennifer DeLuca; Radhika Kanthety; John W Kusek; Claudia M Lora; Lisa Nessel; Ana C Ricardo; Julie Wright Nunes; Michael J Fischer Journal: Clin J Am Soc Nephrol Date: 2016-05-31 Impact factor: 8.237
Authors: Michael J Fischer; Jesse Y Hsu; Claudia M Lora; Ana C Ricardo; Amanda H Anderson; Lydia Bazzano; Magdalena M Cuevas; Chi-Yuan Hsu; John W Kusek; Amada Renteria; Akinlolu O Ojo; Dominic S Raj; Sylvia E Rosas; Qiang Pan; Kristine Yaffe; Alan S Go; James P Lash Journal: J Am Soc Nephrol Date: 2016-05-05 Impact factor: 10.121
Authors: Sarah J Schrauben; Jesse Y Hsu; Sylvia E Rosas; Bernard G Jaar; Xiaoming Zhang; Rajat Deo; Georges Saab; Jing Chen; Swati Lederer; Radhika Kanthety; L Lee Hamm; Ana C Ricardo; James P Lash; Harold I Feldman; Amanda H Anderson Journal: Am J Kidney Dis Date: 2018-03-24 Impact factor: 8.860
Authors: Lilia Cervantes; Michel Chonchol; Romana Hasnain-Wynia; John F Steiner; Edward Havranek; Madelyne Hull; John Rice; Jessica Kendrick; Xochilt Alamillo; Claudia Camacho; Stacy Fischer Journal: J Palliat Med Date: 2019-01-31 Impact factor: 2.947
Authors: Robert G Nelson; V Shane Pankratz; Donica M Ghahate; Jeanette Bobelu; Thomas Faber; Vallabh O Shah Journal: Clin J Am Soc Nephrol Date: 2018-11-15 Impact factor: 8.237